Skip to main content
. 2015 Dec 24;7(4):3847–3856. doi: 10.18632/oncotarget.6758

Figure 3. Effect of EGFR-TKI treatment in subcutaneous and LMC models with PC-9/ffluc cells.

Figure 3

(A) PC-9/ffluc cells were inoculated subcutaneously into SHO-SCID mice (N = 4). Daily oral treatment with erlotinib (25 mg/kg) or AZD9291 (6 mg/kg) was given from day 8 until day 30. (B) PC-9/ffluc cells were inoculated into the leptomeningeal space of SHO-SCID mice (N = 5). Daily oral treatment with erlotinib (25 mg/kg) or AZD9291 (6 mg/kg) was given from day 5 until day 50. Bars represent SD. (C) Representative images of mice treated with or without erlotinib (25 mg/kg) or AZD9291 (6 mg/kg).